Alcon has signed an agreement to receive U.S. commercialization rights to Simbrinza from Novartis, according to a press release.
Simbrinza (brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension) is indicated to reduce IOP in patients with primary open-angle glaucoma or ocular hypertension.
“As the global leader in eye care, the addition of a proven fixed-combination glaucoma therapy is a natural adjacency to our existing portfolio,” Sergio Duplan, president, North America at Alcon, said in the release.
Upon closing, expected in the second quarter of 2021, Alcon will pay